Toripalimab combined with anlotinib for recurrent extensive‑stage small‑cell lung cancer: A case report

The 5-year survival rate of patients with extensive-stage small cell lung cancer (ES-SCLC) is <8%; therefore there is an urgent need for more effective treatment. Although immune checkpoint inhibitors have been widely used to treat lung cancer, the efficacy of anti-programmed death 1 therapy for...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Ying, Chen, Yinqiao, Yang, Zhouliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236139/
https://www.ncbi.nlm.nih.gov/pubmed/37273750
http://dx.doi.org/10.3892/etm.2023.12012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236139/
https://www.ncbi.nlm.nih.gov/pubmed/37273750
http://dx.doi.org/10.3892/etm.2023.12012

Ejemplares similares